# Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

> **NCT00003561** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 48 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00003561
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-02
- **Primary completion:** 2001-10
- **Final completion:** 2010-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2011-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003561, "Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00003561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*